Daiichi Sankyo Company, Limited · TSE:4568

Daiichi Sankyo — ASCO 2018

8 slides from Daiichi Sankyo's conference presentation, May 16, 2018

  1. Slide 1: ASCO 2018 Summary of Presentation

    ASCO 2018 Summary of Presentation May 16, 2018

  2. Slide 2: ASCO: Accepted Presentations

    ASCO: Accepted Presentations  Oral presentations  DS-8201  Pexidartinib  Poster discussions  U3-1402  Quizartinib  DS-3032  Poster presentations  Trial-in-Progress  DS-8201  U3-1402  DS-1062

  3. Slide 3: Important and Interesting ADC Presentations

    Important and Interesting ADC Presentations  DS-8201 Ph1 study (multiple tumor) update  Abstract No: 2501  Oral presentation on June 1st, 2:45 PM – 5:45 PM  U3-1402 Ph1 study (breast cancer) update  Abstract No: 2512  Poster discussion on June 4th, 3:00 PM – 4:15 PM Results will be updated at

  4. Slide 4: ASCO Presentations: DS-8201

    ASCO Presentations: DS-8201 DSI Compound Presentation Tumor Type Lead Author Title Session Type Abstract No: 2501 Trastuzumab deruxtecan Session Name: (DS-8201a) in subjects Developmental with HER2-expressing Therapeutics- Clinical DS-8201 Oral HER2-positive Hiroji Iwata solid tumors: Long-term Phar

  5. Slide 5: ASCO Presentations: ADC Franchise

    ASCO Presentations: ADC Franchise DSI Compound Presentation Tumor Type Lead Author Title Session Type Abstract No: 2512 Session Name: Developmental Therapeutics-Clinical Pharmacology and Single Agent Activity of Experimental Therapeutics U3-1402, a HER3- Poster Metastatic breast Takahiro Targeting A

  6. Slide 6: ASCO Presentations: AML Franchise

    ASCO Presentations: AML Franchise DSI Presentation Tumor Type Lead Author Title Session Compound Type Abstract No.: 7017 Session Name: Hematologic Post hoc exploratory Malignancies-Leukemia, analysis of two phase 2 Myelodysplastic Syndromes, trials of quizartinib and Allotransplant FLT3-ITD- monothe

  7. Slide 7: ASCO Presentations: Breakthrough Science

    ASCO Presentations: Breakthrough Science DSI Compound Presentation Type Tumor Type Lead Author Title Session Final results of ENLIVEN: a global, Abstract No: double-blind, 11502 randomized, Session Name: Pexidartinib Tenosynovial giant- placebo-controlled, Sarcoma Oral Presentation William D. Tap Da

  8. Slide 8: Contact address regarding this material

    Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Email: [email protected]

Daiichi Sankyo Company — ASCO 2018 on 6ix